TBC3711 is a next-generation endothelin antagonist that is being studied through oral and intravenous formulations by Encysive Pharmaceuticals.
- Mechanism
- Curator reviewed
TBC3711 is a small molecule that blocks the action of endothelin, a potent mediator of blood vessel constriction and growth of smooth muscle in vascular walls. It is a next-generation endothelin A antagonist which possesses high oral bioavailability and is more selective and potent than THELIN(tm) (sitaxsentan sodium) Encysive's oral treatment for pulmonary arterial hypertension. TBC3711 is greater than 100,000-fold selective in the targeting of the endothelin A receptor versus the endothelin B receptor.
- Primary indication
- Investigated for use/treatment in congestive heart failure, hypertension, and pulmonary hypertension.Curator reviewed
- Formula / weight
- C20H21N3O5S2 · 447.52 g/mol (avg)
- Code names
- TBC-3711
Resolves to
IAYNHDZSSDUYHY-UHFFFAOYSA-NSMILESCC(=O)C1=C(NC(=O)C2=C(C=CS2)S(=O)(=O)NC2=C(C)C(C)=NO2)C(C)=CC(C)=C1What you can answer from here — as of April 23, 2025
Which drugs share a target with TBC-3711, and which of those have an active Phase 3 trial?
Create a free account or log in to explore the full data card.
Create Account